{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360298345303928320.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.ejmech.2018.08.065"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0223523418307372?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0223523418307372?httpAccept=text/plain"}}],"dc:title":[{"@value":"Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380298345303928320","@type":"Researcher","foaf:name":[{"@value":"Zhong-Ying Ma"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928321","@type":"Researcher","foaf:name":[{"@value":"Dong-Bo Wang"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928325","@type":"Researcher","foaf:name":[{"@value":"Xue-Qing Song"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928327","@type":"Researcher","foaf:name":[{"@value":"Yi-Gang Wu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928323","@type":"Researcher","foaf:name":[{"@value":"Qian Chen"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928324","@type":"Researcher","foaf:name":[{"@value":"Chun-Lai Zhao"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928328","@type":"Researcher","foaf:name":[{"@value":"Jing-Yi Li"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928322","@type":"Researcher","foaf:name":[{"@value":"Shi-Hao Cheng"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345303928326","@type":"Researcher","foaf:name":[{"@value":"Jing-Yuan Xu"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02235234"}],"prism:publicationName":[{"@value":"European Journal of Medicinal Chemistry"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2018-09","prism:volume":"157","prism:startingPage":"1292","prism:endingPage":"1299"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0223523418307372?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0223523418307372?httpAccept=text/plain"}],"createdAt":"2018-08-27","modifiedAt":"2025-10-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/2050870367085358720","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dual-action Pt(Ⅳ) prodrugs and targeted delivery in metal-organic frameworks : overcoming cisplatin resistance and improving anticancer activity"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.ejmech.2018.08.065"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20220218_references_DOI_FRPt3AqV2NC8QgfLUdIUDAIZqAv"}]}